Drug-maker Paragon Bioservices has agreed a $ about $602 million deal to acquire Maryland -based The Wall Street Journal , according to a report in Catalent . The deal is expected to enable Catalent to pursue the development of specialised gene therapy treatments. Neither company has confirmed the report.
Drug-maker Catalent has agreed a $1.2bn deal to acquire Baltimore-based Paragon Bioservices, according to a report in The Wall Street Journal. The deal is expected to enable Catalent to pursue the development of specialised gene therapy treatments. Neither company has confirmed the report.